Trial · NCT00392925
Results by group361
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 361
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Mean Absolute Change From Baseline to Week 16 in Body Weight - Evaluable Population | Metreleptin | -2.68 | Standard Error 0.952 | kg | |
| Mean Absolute Change From Baseline to Week 16 in Body Weight - Evaluable Population | Pramlintide Acetate | -3.30 | Standard Error 0.698 | kg | |
| Mean Absolute Change From Baseline to Week 16 in Body Weight - Evaluable Population | Pramlintide Acetate + Metreleptin | -6.46 | Standard Error 0.682 | kg | |
| LS Mean Percent Change in Body Weight From Baseline to Weeks 4, 8, 12, 16, and 20 - Evaluable Population | Metreleptin | Week 4 (n=19, 38, 36) | -0.70 | Standard Error 0.429 | percentage of change |
| LS Mean Percent Change in Body Weight From Baseline to Weeks 4, 8, 12, 16, and 20 - Evaluable Population | Pramlintide Acetate | Week 4 (n=19, 38, 36) | -1.55 | Standard Error 0.310 | percentage of change |
| LS Mean Percent Change in Body Weight From Baseline to Weeks 4, 8, 12, 16, and 20 - Evaluable Population | Pramlintide Acetate + Metreleptin | Week 4 (n=19, 38, 36) | -2.36 | Standard Error 0.311 | percentage of change |
| LS Mean Percent Change in Body Weight From Baseline to Weeks 4, 8, 12, 16, and 20 - Evaluable Population | Metreleptin | Week 8 (n=19, 38, 36) | -2.08 | Standard Error 0.591 | percentage of change |
| LS Mean Percent Change in Body Weight From Baseline to Weeks 4, 8, 12, 16, and 20 - Evaluable Population | Pramlintide Acetate | Week 8 (n=19, 38, 36) | -2.74 | Standard Error 0.427 | percentage of change |
| LS Mean Percent Change in Body Weight From Baseline to Weeks 4, 8, 12, 16, and 20 - Evaluable Population | Pramlintide Acetate + Metreleptin | Week 8 (n=19, 38, 36) | -4.81 | Standard Error 0.429 | percentage of change |
| LS Mean Percent Change in Body Weight From Baseline to Weeks 4, 8, 12, 16, and 20 - Evaluable Population | Metreleptin | Week 12 (n=19, 38, 36) | -3.17 | Standard Error 0.796 | percentage of change |
| LS Mean Percent Change in Body Weight From Baseline to Weeks 4, 8, 12, 16, and 20 - Evaluable Population | Pramlintide Acetate | Week 12 (n=19, 38, 36) | -3.39 | Standard Error 0.575 | percentage of change |
| LS Mean Percent Change in Body Weight From Baseline to Weeks 4, 8, 12, 16, and 20 - Evaluable Population | Pramlintide Acetate + Metreleptin | Week 12 (n=19, 38, 36) | -6.13 | Standard Error 0.577 | percentage of change |
| LS Mean Percent Change in Body Weight From Baseline to Weeks 4, 8, 12, 16, and 20 - Evaluable Population | Metreleptin | Week 16 (n=19, 38, 36) | -3.37 | Standard Error 1.025 | percentage of change |
| LS Mean Percent Change in Body Weight From Baseline to Weeks 4, 8, 12, 16, and 20 - Evaluable Population | Pramlintide Acetate | Week 16 (n=19, 38, 36) | -3.85 | Standard Error 0.740 | percentage of change |
| LS Mean Percent Change in Body Weight From Baseline to Weeks 4, 8, 12, 16, and 20 - Evaluable Population | Pramlintide Acetate + Metreleptin | Week 16 (n=19, 38, 36) | -7.59 | Standard Error 0.743 | percentage of change |
| LS Mean Percent Change in Body Weight From Baseline to Weeks 4, 8, 12, 16, and 20 - Evaluable Population | Metreleptin | Week 20 (n=19, 37, 36) | -3.62 | Standard Error 1.277 | percentage of change |
| LS Mean Percent Change in Body Weight From Baseline to Weeks 4, 8, 12, 16, and 20 - Evaluable Population | Pramlintide Acetate | Week 20 (n=19, 37, 36) | -3.89 | Standard Error 0.925 | percentage of change |
| LS Mean Percent Change in Body Weight From Baseline to Weeks 4, 8, 12, 16, and 20 - Evaluable Population | Pramlintide Acetate + Metreleptin | Week 20 (n=19, 37, 36) | -8.21 | Standard Error 0.926 | percentage of change |
| LS Mean Absolute Change From Baseline to Weeks 4, 8, 12, 20 in Body Weight - Evaluable Population | Metreleptin | Week 4 (n=19, 38, 36) | -0.66 | Standard Error 0.387 | kg |
| LS Mean Absolute Change From Baseline to Weeks 4, 8, 12, 20 in Body Weight - Evaluable Population | Pramlintide Acetate | Week 4 (n=19, 38, 36) | -1.43 | Standard Error 0.284 | kg |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00392925/results